Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
haemophilia  ||| S:13 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
the  ||| S:28 E:32 ||| DT
elderly  ||| S:32 E:40 ||| JJ
Treatment  ||| S:40 E:50 ||| NNP
of  ||| S:50 E:53 ||| IN
elderly  ||| S:53 E:61 ||| JJ
patients  ||| S:61 E:70 ||| NNS
with  ||| S:70 E:75 ||| IN
haemophilia  ||| S:75 E:87 ||| NN
is  ||| S:87 E:90 ||| VBZ
an  ||| S:90 E:93 ||| DT
upcoming  ||| S:93 E:102 ||| JJ
challenge  ||| S:102 E:112 ||| NN
in  ||| S:112 E:115 ||| IN
haemophilia  ||| S:115 E:127 ||| JJ
care ||| S:127 E:131 ||| NN
.  ||| S:131 E:133 ||| .
We  ||| S:133 E:136 ||| PRP
included  ||| S:136 E:145 ||| VBD
patients  ||| S:145 E:154 ||| NNS
with  ||| S:154 E:159 ||| IN
haemophilia  ||| S:159 E:171 ||| VBG
A  ||| S:171 E:173 ||| DT
older  ||| S:173 E:179 ||| JJR
than  ||| S:179 E:184 ||| IN
60  ||| S:184 E:187 ||| CD
years  ||| S:187 E:193 ||| NNS
of  ||| S:193 E:196 ||| IN
age ||| S:196 E:199 ||| NN
,  ||| S:199 E:201 ||| ,
who  ||| S:201 E:205 ||| WP
visited  ||| S:205 E:213 ||| VBD
our  ||| S:213 E:217 ||| PRP$
haemophilia  ||| S:217 E:229 ||| JJ
centre  ||| S:229 E:236 ||| NN
between  ||| S:236 E:244 ||| IN
2006  ||| S:244 E:249 ||| CD
and  ||| S:249 E:253 ||| CC
2008 ||| S:253 E:257 ||| CD
.  ||| S:257 E:259 ||| .
We  ||| S:259 E:262 ||| PRP
conducted  ||| S:262 E:272 ||| VBD
a  ||| S:272 E:274 ||| DT
retrospective  ||| S:274 E:288 ||| JJ
study  ||| S:288 E:294 ||| NN
focussing  ||| S:294 E:304 ||| NN
on  ||| S:304 E:307 ||| IN
the  ||| S:307 E:311 ||| DT
patients ||| S:311 E:319 ||| NNS
'  ||| S:319 E:321 ||| POS
co-morbidities  ||| S:321 E:336 ||| JJ
as  ||| S:336 E:339 ||| IN
well  ||| S:339 E:344 ||| RB
as  ||| S:344 E:347 ||| IN
changes  ||| S:347 E:355 ||| NNS
in  ||| S:355 E:358 ||| IN
their  ||| S:358 E:364 ||| PRP$
bleeding  ||| S:364 E:373 ||| JJ
patterns  ||| S:373 E:382 ||| NNS
between  ||| S:382 E:390 ||| IN
2003  ||| S:390 E:395 ||| CD
and  ||| S:395 E:399 ||| CC
2008 ||| S:399 E:403 ||| CD
.  ||| S:403 E:405 ||| .
There  ||| S:405 E:411 ||| EX
is  ||| S:411 E:414 ||| VBZ
a  ||| S:414 E:416 ||| DT
tendency  ||| S:416 E:425 ||| NN
of  ||| S:425 E:428 ||| IN
increasing  ||| S:428 E:439 ||| VBG
bleeding  ||| S:439 E:448 ||| JJ
symptoms  ||| S:448 E:457 ||| NNS
with  ||| S:457 E:462 ||| IN
increasing  ||| S:462 E:473 ||| VBG
age  ||| S:473 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
the  ||| S:480 E:484 ||| DT
patients  ||| S:484 E:493 ||| NNS
due  ||| S:493 E:497 ||| JJ
to  ||| S:497 E:500 ||| TO
more  ||| S:500 E:505 ||| RBR
frequent  ||| S:505 E:514 ||| JJ
spontaneous  ||| S:514 E:526 ||| JJ
joint  ||| S:526 E:532 ||| JJ
bleedings ||| S:532 E:541 ||| NN
,  ||| S:541 E:543 ||| ,
malignancies  ||| S:543 E:556 ||| NN
or  ||| S:556 E:559 ||| CC
treatment  ||| S:559 E:569 ||| NN
with  ||| S:569 E:574 ||| IN
phenprocoumon  ||| S:574 E:588 ||| NN
or  ||| S:588 E:591 ||| CC
ASS ||| S:591 E:594 ||| NNP
.  ||| S:594 E:596 ||| .
In  ||| S:596 E:599 ||| IN
consequence ||| S:599 E:610 ||| NN
,  ||| S:610 E:612 ||| ,
FVIII  ||| S:612 E:618 ||| NNP
dosage  ||| S:618 E:625 ||| NN
had  ||| S:625 E:629 ||| VBD
to  ||| S:629 E:632 ||| TO
be  ||| S:632 E:635 ||| VB
increased  ||| S:635 E:645 ||| VBN
for  ||| S:645 E:649 ||| IN
8  ||| S:649 E:651 ||| CD
patients  ||| S:651 E:660 ||| NNS
( ||| S:660 E:661 ||| -LRB-
28 ||| S:661 E:663 ||| CD
% ||| S:663 E:664 ||| NN
) ||| S:664 E:665 ||| -RRB-
.  ||| S:665 E:667 ||| .
Chronic  ||| S:667 E:675 ||| NNP
hepatitis  ||| S:675 E:685 ||| NNP
C ||| S:685 E:686 ||| NNP
,  ||| S:686 E:688 ||| ,
coronary  ||| S:688 E:697 ||| JJ
heart  ||| S:697 E:703 ||| NN
disease  ||| S:703 E:711 ||| NN
and  ||| S:711 E:715 ||| CC
malignancies  ||| S:715 E:728 ||| NNS
are  ||| S:728 E:732 ||| VBP
the  ||| S:732 E:736 ||| DT
most  ||| S:736 E:741 ||| RBS
frequent  ||| S:741 E:750 ||| JJ
co-morbidities ||| S:750 E:764 ||| NN
.  ||| S:764 E:766 ||| .
